Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference
Akari Therapeutics (Nasdaq: AKTX) announced that CEO Abizer Gaslightwala will present in person at the 2026 Biocom Global Partnering & Investor Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Akari Therapeutics (Nasdaq: AKTX) announced that CEO Abizer Gaslightwala will present in person at the 2026 Biocom Global Partnering & Investor Conference.
The presentation is scheduled for Wednesday, February 25, 2026 at 11:00 AM PST in Track B, and management will be available for one-on-one meetings with registered investors.
Details
News Market Reaction – AKTX
On Feb 18, the day this news came out, AKTX closed 1.64% below the previous close.
Data tracked by StockTitan Argus for the Feb 18 session.
Key Figures
- Conference presentation time
- 11:00 AM PT, Feb 25, 2026
- Biocom Global Partnering & Investor Conference in-person talk
- Conference dates
- February 24–26, 2026
- Biocom Global Partnering & Investor Conference schedule
- ADSs registered for resale
- 34,680,906 ADSs
- S-1 resale registration tied to warrants and financings
- Potential warrant proceeds
- $8.9 million
- Maximum cash if related warrants exercised in full
- Cash balance
- about $2.5 million
- Reported as of September 30, 2025 in S-1
- ADSs outstanding
- 45,781,350 ADSs
- Outstanding as of January 22, 2026 per S-1
- Registered direct offering size
- 10,043,774 ADSs
- ADSs sold at $0.3883 per ADS in Dec 2025
- Gross proceeds from Dec 2025 offer
- $3,899,997
- Registered direct offering before fees, Dec 17, 2025
Historical Context
-
CEO discussed expanded ADC pipeline and new AKTX-102 program.
-
Corporate overview of ADC platform and timelines for AKTX-101/102.
-
Filed key patent and unveiled AKTX-102 targeting CEACAM5 tumors.
-
CEO Corner on 2025 progress and path to clinical transition.
-
Announcement of in-person presentation at 2026 Biotech Showcase.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
antibody drug conjugates medical
ADCs medical
immuno-oncology medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
In-person presentation on Wednesday, February 25th at 11:00 AM PT
TAMPA, Fla. and LONDON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today announced that Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, will present at the 2026 Biocom Global Partnering & Investor Conference, being held February 24–26, 2026, at The Lodge at Torrey Pines in San Diego, CA.
Presentation details are as follows:
Date/Time: Wednesday, February 25, 2026, at 11:00 AM PST
Location: Track B
In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.
About Akari Therapeutics
Akari Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any antigen target of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. Unlike current ADCs that use tubulin inhibitors and DNA damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating both the innate and adaptive immune system to drive robust and durable activity. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors. The PH1 payload has also been demonstrated to be very active against cancer cells with key oncogenic drivers such as KRAS, BRAF, ARV7, FGFR3 fusions, and others. The Company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by late 2026/early 2027. Akari is also developing AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen broadly expressed across multiple solid tumors. AKTX-102 is designed to leverage Akari’s proprietary PH1 spliceosome-modulating payload and novel antibody construct to enable differentiated tumor cell killing and immune activation.
For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
AKTX@jtcir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.